The shares were sold at an average price of $107.31, for a total value of $1,982,981.49. The company has a market cap of $2,915.93, a P/E ratio of 103.88, a P/E/G ratio of 2.12 and a beta of 0.91.
Infosys Limited Ads (NYSE:INFY) had a decrease of 0.87% in short interest. INFY's SI was 77.75 million shares in January as released by FINRA.
Since September 21, 2017, it had 0 insider buys, and 6 insider sales for $22.31 million activity. (LGND) traded up $0.95 during mid-day trading on Friday, reaching $148.90. 313,897 shares of the company traded hands. The companyÂ's products include Finacle, a banking solution that provides analytics, core banking, consumer e-banking, corporate e-banking, Islamic banking, mobile banking, origination, payments, SME enable, treasury, wealth management, and youth banking solutions. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. Therefore 19% are positive. The rating was reinitiated by H.C. Wainwright on Tuesday, September 5 with "Buy". The stock of FedEx Corporation (NYSE:FDX) earned "Buy" rating by UBS on Friday, June 3. The company was maintained on Tuesday, October 3 by Robert W. Baird. The firm has "Buy" rating given on Friday, December 18 by Roth Capital. As per Monday, August 21, the company rating was downgraded by JP Morgan. The stock increased 1.19% or $3.18 during the last trading session, reaching $271.19. It has underperformed by 19.57% the S&P500.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is worth US$3.06 Billion and has recently risen 2.21% to US$144.25. After $0.55 actual earnings per share reported by Ligand Pharmaceuticals Incorporated for the previous quarter, Wall Street now forecasts 67.27% EPS growth.
Among 6 analysts covering Ligand Pharmaceuticals (NASDAQ:LGND), 5 have Buy rating, 1 Sell and 0 Hold. Therefore 83% are positive. Ligand Pharmaceuticals has a 1-year low of $95.08 and a 1-year high of $149.31. The company's net profit margin has achieved the current level of 37.4 percent and possesses 0 percent gross margin. Ligand Pharmaceuticals had 23 analyst reports since September 3, 2015 according to SRatingsIntel. Shares for $11.89M were sold by BRONCZEK DAVID J on Tuesday, January 2. Bank of America has "Buy" rating and $293.0 target. The firm has "Buy" rating by TH Capital given on Wednesday, September 30. On Thursday, November 19 the stock rating was maintained by TH Capital with "Buy". Deutsche Bank maintained the shares of LGND in report on Monday, July 17 with "Hold" rating. The rating was maintained by H.C. Wainwright with "Buy" on Thursday, November 9. The firm has "Buy" rating by Roth Capital given on Thursday, September 3. The firm earned "Buy" rating on Friday, March 11 by Roth Capital.
Since August 8, 2017, it had 0 insider buys, and 6 selling transactions for $4.86 million activity. Also, Director Stephen L. Sabba sold 925 shares of the company's stock in a transaction dated Wednesday, December 20th. On Wednesday, August 9 Berkman Charles S sold $2.36 million worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) or 18,625 shares. FOEHR MATTHEW W sold $777,824 worth of stock. With 287,200 avg volume, 13 days are for Ligand Pharmaceuticals (NASDAQ:LGND)'s short sellers to cover LGND's short positions.
Investors sentiment increased to 1.69 in Q3 2017. Its up 0.45, from 1.24 in 2017Q2. Strs Ohio lifted its holdings in Ligand Pharmaceuticals by 225.0% in the 2nd quarter. 50 funds opened positions while 97 raised stakes. Meridian Counsel invested 0.23% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Keybank National Association Oh reported 2,416 shares. It also reduced Middleby Corp (NASDAQ:MIDD) stake by 5,475 shares and now owns 15,134 shares. Paloma Prtnrs Management invested 0% of its portfolio in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Dekabank Deutsche Girozentrale invested 0.01% of its portfolio in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Creative Planning reported 0.01% stake. Dimensional Fund Advsrs Lp accumulated 237,130 shares. Macquarie Group Ltd. boosted its stake in Ligand Pharmaceuticals by 27.3% during the 2nd quarter. Gemmer Asset Limited holds 0% of its portfolio in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) for 53 shares. Arizona State Retirement System reported 10,875 shares stake. Citigroup Inc stated it has 31,162 shares or 0% of all its holdings. At present, 0 analysts call it Sell, while 3 think it is Hold.
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company's commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; CorMatrix portfolio of vascular, cardiac, and pericardial tissue fix products; bazedoxifene, which is used for the treatment of postmenopausal osteoporosis; Carnexiv that is used as replacement therapy for oral carbamazepine formulations; Nexterone, a Captisol-enabled formulation of amiodarone; Noxafil-IV, a Captisol-enabled formulation of posaconazole for IV use; Exemptia for autoimmune diseases; and Vivitra for breast cancer. The Company is involved in the development and licensing of biopharmaceutical assets. Recently, analysts have updated the overall rating to 2.11.